Unblinding at disease progression in double-blinded randomized controlled cancer drug clinical trials: A controversy requires more attention

Unblinding at disease progression in double-blinded randomized controlled cancer drug clinical trials is ethical to the patient by ensuring optimal subsequent treatment, but the effect of study treatment on overall survival may be confounded. The views of science and ethics in this issue are controv...

Descripción completa

Detalles Bibliográficos
Autores principales: Dawei, Wu, Shuangman, Miao, Huiyao, Huang, Dandan, Cui, Yu, Tang, Ning, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792660/
https://www.ncbi.nlm.nih.gov/pubmed/36582284
http://dx.doi.org/10.3389/fmed.2022.1082445

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792660/
https://www.ncbi.nlm.nih.gov/pubmed/36582284
http://dx.doi.org/10.3389/fmed.2022.1082445

Ejemplares similares